In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin
1997

Drug Resistance in Small-Cell Lung Cancer

Sample size: 7 publication Evidence: moderate

Author Information

Author(s): PB Jensen, B Holm, M Sorensen, IJ Christensen, M Sehested

Primary Institution: The Finsen Center, Rigshospitalet, Copenhagen, Denmark

Hypothesis

Can drug-resistant small-cell lung cancer cell lines be used to identify effective drug combinations?

Conclusion

The study found that certain drug combinations can overcome resistance in small-cell lung cancer cell lines.

Supporting Evidence

  • Drug resistance was found to be highly drug specific.
  • Patterns of collateral sensitivity were observed in multiple drug-resistant cell lines.
  • Certain drug combinations showed promise in overcoming resistance.

Takeaway

Some cancer cells can resist treatment, but by mixing different drugs, we can find better ways to fight them.

Methodology

The study used a clonogenic assay to measure drug sensitivity in various resistant small-cell lung cancer cell lines.

Limitations

The findings may not directly translate to clinical settings due to the complexity of human tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication